CDR recommends reimbursement for schizophrenia drug, ABILIFY

Links shared publicly online about this topic.

128
total visits

CDR recommends reimbursement for schizophrenia drug, ABILIFY

Bristol-Myers Squibb Canada is pleased to announce that the Common Drug Review (CDR) has recognized the value of ABILIFY® (aripiprazole) for the treatment of schizophrenia and schizoaffective disorders by recommending it be reimbursed by provincial drug plans for patients who have a contraindication to less-expensive antipsychotic agents or who have failed a trial of less expensive antipsychotic agents due to intolerance or lack of response.

View full resource at news-medical.net

Tags: HIV, AIDS, STD, Schizophrenia, Schizophrenia Medication, Psychotic Disorder, Drug, News